| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 20.05% | HSBC | → $22 | Upgrades | Hold → Buy |
| 08/02/2023 | -18.14% | Citigroup | $6.28 → $15 | Maintains | Sell |
| 07/31/2023 | 25.51% | UBS | → $23 | Downgrades | Buy → Neutral |
| 07/28/2023 | 38.06% | Jefferies | $7.8 → $25.3 | Upgrades | Hold → Buy |
| 07/21/2023 | -45.43% | JP Morgan | $7.5 → $10 | Downgrades | Neutral → Underweight |
| 07/11/2023 | — | Goldman Sachs | Initiates Coverage On | → Buy | |
| 07/07/2023 | -42.7% | BOCOM International | → $10.5 | Downgrades | Neutral → Sell |
| 06/30/2023 | -28.51% | CLSA | $10 → $13.1 | Upgrades | Buy → Outperform |
| 06/16/2023 | -36.15% | B of A Securities | $9.8 → $11.7 | Maintains | Neutral |
| 05/25/2023 | -46.52% | B of A Securities | $11 → $9.8 | Maintains | Neutral |
| 05/25/2023 | -67.26% | Barclays | $8 → $6 | Downgrades | Equal-Weight → Underweight |
| 04/25/2023 | -49.25% | Jefferies | $4.2 → $9.3 | Upgrades | Underperform → Hold |
| 03/24/2023 | -34.52% | Bernstein | $16 → $12 | Downgrades | Outperform → Market Perform |
| 03/18/2023 | -41.61% | B of A Securities | $11 → $10.7 | Maintains | Neutral |
| 01/11/2023 | -50.89% | JP Morgan | $11 → $9 | Downgrades | Overweight → Neutral |
| 01/06/2023 | — | B of A Securities | Downgrades | Buy → Neutral | |
| 12/14/2022 | -56.34% | Daiwa Capital | $13 → $8 | Downgrades | Buy → Sell |
| 12/13/2022 | -18.14% | HSBC | $34 → $15 | Maintains | Buy |
| 12/02/2022 | -38.34% | China Renaissance | $40.5 → $11.3 | Downgrades | Buy → Hold |
| 11/28/2022 | -77.08% | Jefferies | $18.6 → $4.2 | Downgrades | Hold → Underperform |
| 11/17/2022 | -29.06% | UBS | $34 → $13 | Upgrades | Neutral → Buy |
| 10/28/2022 | -82.65% | Citigroup | → $3.18 | Downgrades | Buy → Sell |
| 10/28/2022 | -56.34% | Barclays | $22 → $8 | Maintains | Equal-Weight |
| 08/24/2022 | 52.09% | Citigroup | $51.59 → $27.87 | Maintains | Buy |
| 08/24/2022 | 20.05% | Barclays | $30 → $22 | Downgrades | Overweight → Equal-Weight |
| 08/03/2022 | 36.43% | Macquarie | → $25 | Downgrades | Outperform → Neutral |
| 07/01/2022 | 98.09% | Nomura Instinet | → $36.3 | Downgrades | Buy → Neutral |
| 06/21/2022 | 181.53% | Citigroup | $36.7 → $51.59 | Maintains | Buy |
| 05/24/2022 | 91% | JP Morgan | $42 → $35 | Maintains | Overweight |
| 05/24/2022 | 63.71% | Barclays | $39 → $30 | Maintains | Overweight |
| 05/24/2022 | 118.28% | B of A Securities | $46 → $40 | Maintains | Buy |
| 03/29/2022 | 265.62% | Citigroup | $92 → $67 | Maintains | Buy |
| 03/29/2022 | 112.82% | Barclays | $45 → $39 | Maintains | Overweight |
| 03/24/2022 | 203.41% | China Renaissance | → $55.6 | Initiates Coverage On | → Buy |
| 03/23/2022 | — | CLSA | Initiates Coverage On | → Buy | |
| 03/23/2022 | 129.2% | Morgan Stanley | $71 → $42 | Maintains | Overweight |
| 02/08/2022 | — | Barclays | Initiates Coverage On | → Overweight | |
| 01/12/2022 | — | Macquarie | Initiates Coverage On | → Outperform | |
| 11/24/2021 | 260.16% | B of A Securities | $63 → $66 | Maintains | Buy |
| 10/28/2021 | 205.59% | Bernstein | → $56 | Initiates Coverage On | → Outperform |
| 08/27/2021 | 232.88% | B of A Securities | $56 → $61 | Maintains | Buy |
| 05/26/2021 | 156.48% | Nomura Instinet | → $47 | Initiates Coverage On | → Buy |
| 03/09/2021 | 85.54% | Daiwa Capital | → $34 | Upgrades | Sell → Buy |
| 01/29/2021 | 281.99% | Morgan Stanley | → $70 | Initiates Coverage On | → Overweight |
| 01/19/2021 | 196.86% | Jefferies | → $54.4 | Initiates Coverage On | → Hold |
| 01/04/2021 | 195.23% | B of A Securities | $51.1 → $54.1 | Maintains | Buy |
| 12/14/2020 | 216.51% | Deutsche Bank | → $58 | Initiates Coverage On | → Buy |
| 12/03/2020 | 221.96% | UBS | → $59 | Downgrades | Buy → Neutral |
| 11/16/2020 | 214.92% | Citigroup | $34.7 → $57.71 | Maintains | Buy |
| 11/04/2020 | 89.36% | Citigroup | → $34.7 | Initiates Coverage On | → Buy |
| 09/25/2020 | 36.43% | UBS | → $25 | Initiates Coverage On | → Buy |
What is the target price for XPeng (XPEV)?
The latest price target for XPeng (NYSE: XPEV) was reported by HSBC on August 7, 2023. The analyst firm set a price target for $22.00 expecting XPEV to rise to within 12 months (a possible 20.05% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for XPeng (XPEV)?
The latest analyst rating for XPeng (NYSE: XPEV) was provided by HSBC, and XPeng upgraded their buy rating.
When is the next analyst rating going to be posted or updated for XPeng (XPEV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of XPeng, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for XPeng was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
Is the Analyst Rating XPeng (XPEV) correct?
While ratings are subjective and will change, the latest XPeng (XPEV) rating was a upgraded with a price target of $0.00 to $22.00. The current price XPeng (XPEV) is trading at is $18.33, which is within the analyst's predicted range.